Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Pharma Journey: Inferring the Approximate Structure of KT-621 from ...
Kymera Therapeutics Unveils Preclinical Data for Oral STAT6 Degrader KT ...
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT ...
STAT6 PROTAC:从专利中推测KT-621的大致结构（前瞻篇） - 知乎
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL ...
The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene ...
Introducing KT-621, a new oral STAT6 degrader | Kymera Therapeutics ...
KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 ...
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 ...
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in ...
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent ...
Kymera Therapeutics Reveals New Preclinical Data for KT-621, an Oral ...
FDA Approves Kymera Therapeutics' IND Application for Novel Oral STAT6 ...
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b ...
POTENT AND SELECTIVE ORAL STAT6 DEGRADER KT-621 INHIBITS IL-4/IL-13 IN ...
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 ...
From Target Selection to POC in Patients: Completing the Initial Human ...
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug ...
Kymera Therapeutics' KT-621 and the Emergence of Oral STAT6 Degraders ...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First ...
Kymera's KT-621 Shows 90%+ STAT6 Degradation in Phase 1 Trial | KYMR ...
KT-621 Produces 98% STAT6 Degradation in AD Patients | Dermatology Times
砖家预测： 2024 年可能被 FDA 批准上市 PROTAC 热门分子 - 知乎
KT-621：遥遥领先的口服STAT6 PROTAC降解剂
